Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo

Br J Cancer. 1996 Aug;74(3):387-93. doi: 10.1038/bjc.1996.370.


We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs] and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and protein expression, induces growth arrest in the G1 phase of the cell cycle, and inhibits cell proliferation. In vivo treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This comparative study, using the same tumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs might be useful in the therapy of colon cancer in combination with antineoplastic drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Base Sequence
  • Cell Division / drug effects
  • Cisplatin / pharmacology*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Humans
  • Mice
  • Molecular Sequence Data
  • Oligonucleotides, Antisense / pharmacology*
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins c-myb
  • Proto-Oncogenes / physiology*
  • RNA, Messenger / analysis
  • Thionucleotides / pharmacology*
  • Trans-Activators / genetics*
  • Tumor Cells, Cultured


  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-myb
  • RNA, Messenger
  • Thionucleotides
  • Trans-Activators
  • Cisplatin